Cardiovascular Business |
ACC offers guidance on using diabetes drugs for CV event reduction
Cardiovascular Business A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic ... |
from diabetes - Google News
Social Plugin